<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Coherus Biosciences Inc — News on 6ix</title>
<link>https://6ix.com/company/coherus-biosciences-inc</link>
<description>Latest news and press releases for Coherus Biosciences Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 09 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/coherus-biosciences-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835557278dffbe2df0e951b.webp</url>
<title>Coherus Biosciences Inc</title>
<link>https://6ix.com/company/coherus-biosciences-inc</link>
</image>
<item>
<title>Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/coherus-biosciences-inc/news/coherus-oncology-reports-full-year-and-fourth-quarter-2025-financial-results-and-provides-business-update-4</link>
<guid isPermaLink="true">https://6ix.com/company/coherus-biosciences-inc/news/coherus-oncology-reports-full-year-and-fourth-quarter-2025-financial-results-and-provides-business-update-4</guid>
<pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
<description>– LOQTORZI® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 – – Reduced secured and convertible debt by 90% from $480</description>
</item>
<item>
<title>Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026</title>
<link>https://6ix.com/company/coherus-biosciences-inc/news/coherus-oncology-to-report-full-year-and-fourth-quarter-2025-financial-results-on-march-9-2026</link>
<guid isPermaLink="true">https://6ix.com/company/coherus-biosciences-inc/news/coherus-oncology-to-report-full-year-and-fourth-quarter-2025-financial-results-on-march-9-2026</guid>
<pubDate>Mon, 02 Mar 2026 14:30:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its full year and fourth quarter 2025 financial results will be released after market close on Monday, March 9, 2026. Starting at 4:30 p.m. Eastern Time on March 9, 2026, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following t</description>
</item>
<item>
<title>Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock</title>
<link>https://6ix.com/company/coherus-biosciences-inc/news/coherus-oncology-inc-announces-closing-211100814</link>
<guid isPermaLink="true">https://6ix.com/company/coherus-biosciences-inc/news/coherus-oncology-inc-announces-closing-211100814</guid>
<pubDate>Tue, 17 Feb 2026 21:11:00 GMT</pubDate>
<description>–The Offering was led by healthcare-dedicated investors including Janus Henderson Investors, HBM Healthcare Investments and Samsara BioCapital– REDWOOD CITY, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (“Coherus” or the “Company”) (NASDAQ: CHRS), today announced the closing of an underwritten public offering of 28,600,000 shares of the Company’s common stock (the “Offering”). The shares of common stock were sold at a public offering price of $1.75 per share, before underwrit</description>
</item>
<item>
<title>Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock</title>
<link>https://6ix.com/company/coherus-biosciences-inc/news/coherus-oncology-inc-announces-pricing-021800755</link>
<guid isPermaLink="true">https://6ix.com/company/coherus-biosciences-inc/news/coherus-oncology-inc-announces-pricing-021800755</guid>
<pubDate>Fri, 13 Feb 2026 02:18:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (“Coherus” or the “Company”) (NASDAQ: CHRS), today announced the pricing of an underwritten public offering of 28,600,000 shares of the Company’s common stock (the “Offering”). The shares of common stock are being sold at a public offering price of $1.75 per share, before underwriting discounts and commissions. All of the shares in the Offering are being sold by the Company. The gross proceeds to Coherus from the Offe</description>
</item>
<item>
<title>Coherus Oncology, Inc. Announces Proposed Public Offering of Common Stock</title>
<link>https://6ix.com/company/coherus-biosciences-inc/news/coherus-oncology-inc-announces-proposed-210500550</link>
<guid isPermaLink="true">https://6ix.com/company/coherus-biosciences-inc/news/coherus-oncology-inc-announces-proposed-210500550</guid>
<pubDate>Thu, 12 Feb 2026 21:05:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (“Coherus” or the “Company”) (NASDAQ: CHRS), today announced a proposed underwritten public offering of its common stock (the “Offering”). In addition, Coherus intends to grant the underwriters a 30-day option to purchase additional shares of its common stock in an amount up to 15% of the shares offered in the Offering, at the public offering price per share less underwriting discounts and commissions. All of the shar</description>
</item>
<item>
<title>Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/coherus-biosciences-inc/news/coherus-management-present-44th-annual-143000454</link>
<guid isPermaLink="true">https://6ix.com/company/coherus-biosciences-inc/news/coherus-management-present-44th-annual-143000454</guid>
<pubDate>Tue, 06 Jan 2026 14:30:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that senior management will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 10:30 a.m. Pacific Time. The presentation and Q&A session will be accessible via webcast through a link posted on the Investor Events Calendar section of the Coherus website: https://investors.coherus.com/events-presentations. This webcast will be available for replay</description>
</item>
<item>
<title>Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)</title>
<link>https://6ix.com/company/coherus-biosciences-inc/news/coherus-oncology-announces-publication-molecular-143000975</link>
<guid isPermaLink="true">https://6ix.com/company/coherus-biosciences-inc/news/coherus-oncology-announces-publication-molecular-143000975</guid>
<pubDate>Mon, 05 Jan 2026 14:30:00 GMT</pubDate>
<description>-Coherus Oncology formally introduces non-proprietary name: tagmokitug- -Publication shows picomolar affinity for CCR8 with no off-target binding and proof-of- mechanism in preclinical and clinical studies- -Data show CCR8 target is present with high prevalence and density in many solid tumors- REDWOOD CITY, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced the publication of preclinical and clinical biomarker research in Molecular Cancer Therapeutic</description>
</item>
<item>
<title>Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma</title>
<link>https://6ix.com/company/coherus-biosciences-inc/news/coherus-announces-six-jupiter-02-133000087</link>
<guid isPermaLink="true">https://6ix.com/company/coherus-biosciences-inc/news/coherus-announces-six-jupiter-02-133000087</guid>
<pubDate>Mon, 08 Dec 2025 13:30:00 GMT</pubDate>
<description>-6 Years Long-term survival data reinforce potential benefit to patient survival in treating recurrent or metastatic nasopharyngeal carcinoma with LOQTORZI in combination with chemotherapy -REDWOOD CITY, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced compelling six-year overall survival (OS) follow-up results from the Phase 3 JUPITER-02 trial evaluating LOQTORZI® (toripalimab-tpzi) plus chemotherapy in recurrent or metastatic nasopharyngeal carcin</description>
</item>
<item>
<title>Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody</title>
<link>https://6ix.com/company/coherus-biosciences-inc/news/coherus-oncology-presents-sitc-clinical-140000070</link>
<guid isPermaLink="true">https://6ix.com/company/coherus-biosciences-inc/news/coherus-oncology-presents-sitc-clinical-140000070</guid>
<pubDate>Fri, 07 Nov 2025 14:00:00 GMT</pubDate>
<description>– CHS-114 demonstrated robust and selective depletion of CCR8+ Tregs as well as favorable immune remodeling in tumor tissue from head and neck squamous cell carcinoma (HNSCC) patients – – CHS-114 administration resulted in selective depletion of CCR8+ Tregs and a >50% increase in intratumoral CD8 T cells – turning tumors “hot” REDWOOD CITY, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS), today announced new multiomic tumor and blood-based biomarker data from the</description>
</item>
<item>
<title>Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/coherus-biosciences-inc/news/coherus-oncology-reports-third-quarter-211400526</link>
<guid isPermaLink="true">https://6ix.com/company/coherus-biosciences-inc/news/coherus-oncology-reports-third-quarter-211400526</guid>
<pubDate>Thu, 06 Nov 2025 21:14:00 GMT</pubDate>
<description>– CHS-114, a highly selective Treg depleter, clinical program expanded to include colorectal cancer – – Q3 2025 ending cash, cash equivalents and marketable securities of $191.7 million – – LOQTORZI® net revenue was $11.2 million, a 12% increase over Q2 2025 – – Conference call today at 5:00 p.m. Eastern Standard Time – REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today reported financial results for the third quarter ended September 30, 2025 and</description>
</item>
<item>
<title>Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer</title>
<link>https://6ix.com/company/coherus-biosciences-inc/news/arvind-sood-joins-coherus-oncology-185400347</link>
<guid isPermaLink="true">https://6ix.com/company/coherus-biosciences-inc/news/arvind-sood-joins-coherus-oncology-185400347</guid>
<pubDate>Thu, 06 Nov 2025 18:54:00 GMT</pubDate>
<description>– Responsible for Corporate Development, Investor Relations, Government Affairs – REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that Arvind Sood has joined the Company as Chief Strategy and Corporate Affairs Officer reporting to Denny Lanfear, Chairman and Chief Executive Officer. Mr. Sood’s responsibilities include key externally facing and strategic functions. “We are thrilled to have a such a well-regarded senior biotechnology e</description>
</item>
<item>
<title>Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025</title>
<link>https://6ix.com/company/coherus-biosciences-inc/news/coherus-oncology-report-third-quarter-123000709</link>
<guid isPermaLink="true">https://6ix.com/company/coherus-biosciences-inc/news/coherus-oncology-report-third-quarter-123000709</guid>
<pubDate>Thu, 30 Oct 2025 12:30:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its third quarter 2025 financial results will be released after market close on Thursday, November 6, 2025. Starting at 5:00 p.m. Eastern Time on November 6, 2025, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following the concl</description>
</item>
<item>
<title>Coherus Oncology to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/coherus-biosciences-inc/news/coherus-oncology-participate-upcoming-investor-123000674</link>
<guid isPermaLink="true">https://6ix.com/company/coherus-biosciences-inc/news/coherus-oncology-participate-upcoming-investor-123000674</guid>
<pubDate>Thu, 23 Oct 2025 12:30:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that the company will be webcasting its presentations at the following upcoming conferences: UBS Global Healthcare Conference in Palm Beach Gardens, FL on Monday, November 10, 2025, at 1:15 p.m. Eastern Time / 10:15 a.m. Pacific TimeJefferies Global Healthcare Conference in London, England on Tuesday, November 18, 2025, at 10:30 a.m. Greenwich Mean Time / 5:30 a.m. Eastern TimeBaird Biot</description>
</item>
<item>
<title>Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)</title>
<link>https://6ix.com/company/coherus-biosciences-inc/news/coherus-oncology-announces-poster-presentation-130500898</link>
<guid isPermaLink="true">https://6ix.com/company/coherus-biosciences-inc/news/coherus-oncology-announces-poster-presentation-130500898</guid>
<pubDate>Fri, 03 Oct 2025 13:05:00 GMT</pubDate>
<description>– CHS-114, an anti-CCR8 cytolytic antibody, will also be featured in SITC’s upcoming webinar series “Targets for Cancer IO: A Deep Dive” on October 22, 2025 –REDWOOD CITY, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS), today announced an upcoming poster presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held November 5-9, 2025, in National Harbor, Maryland. Abstract # 640: CHS-114, an anti-CCR8 cytolytic monoclonal an</description>
</item>
<item>
<title>Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/coherus-biosciences-inc/news/coherus-oncology-reports-second-quarter-204100799</link>
<guid isPermaLink="true">https://6ix.com/company/coherus-biosciences-inc/news/coherus-oncology-reports-second-quarter-204100799</guid>
<pubDate>Thu, 07 Aug 2025 20:41:00 GMT</pubDate>
<description>– LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 – – Data readouts for CHS-114 and casdozokitug on track for 1H 2026 – – Q2 2025 ending cash, cash equivalents and marketable securities of $238 million – – Conference call today at 5:00 p.m. Eastern Time – REDWOOD CITY, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today reported financial results for the second quarter ended June 30, 2025 and provided an overview of recent business highlight</description>
</item>
<item>
<title>Intas Pharmaceuticals and Accord BioPharma Become One of the Largest Global Suppliers of Pegfilgrastim with Acquisition of UDENYCA®</title>
<link>https://6ix.com/company/coherus-biosciences-inc/news/intas-pharmaceuticals-and-accord-biopharma-become-one-of-the-largest-global-suppliers-of-pegfilgrastim-with-acquisition-of-udenycar</link>
<guid isPermaLink="true">https://6ix.com/company/coherus-biosciences-inc/news/intas-pharmaceuticals-and-accord-biopharma-become-one-of-the-largest-global-suppliers-of-pegfilgrastim-with-acquisition-of-udenycar</guid>
<pubDate>Wed, 06 Aug 2025 14:29:00 GMT</pubDate>
<description>Intas Pharmaceuticals in collaboration with its global subsidiaries operating under the Accord brand, has solidified its position as one of the world's leading suppliers of pegfilgrastim following the successful acquisition of UDENYCA® (pegfilgrastim-cbqv) from Coherus BioSciences, Inc.</description>
</item>
<item>
<title>Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025</title>
<link>https://6ix.com/company/coherus-biosciences-inc/news/coherus-oncology-report-second-quarter-204500176</link>
<guid isPermaLink="true">https://6ix.com/company/coherus-biosciences-inc/news/coherus-oncology-report-second-quarter-204500176</guid>
<pubDate>Thu, 31 Jul 2025 20:45:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus, Coherus Oncology or the Company, Nasdaq: CHRS), today announced that its second quarter 2025 financial results will be released after market close on Thursday, August 7, 2025. Starting at 5:00 p.m. EDT on August 7, 2025, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.c</description>
</item>
<item>
<title>Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics</title>
<link>https://6ix.com/company/coherus-biosciences-inc/news/coherus-completes-strategic-transformation-coherus-120000241</link>
<guid isPermaLink="true">https://6ix.com/company/coherus-biosciences-inc/news/coherus-completes-strategic-transformation-coherus-120000241</guid>
<pubDate>Fri, 30 May 2025 12:00:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus Oncology, Nasdaq: CHRS), a commercial-stage innovative oncology company, formerly named Coherus BioSciences Inc., announced its name change today to better align with its exclusive focus on proprietary innovative immuno-oncology medicines. “The field of cancer immunotherapy has been reinvigorated by the promise and power of combination therapies. Coherus Oncology has the expertise and pipeline to become a sign</description>
</item>
<item>
<title>Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi)</title>
<link>https://6ix.com/company/coherus-biosciences-inc/news/coherus-announces-clinical-collaboration-storm-123000609</link>
<guid isPermaLink="true">https://6ix.com/company/coherus-biosciences-inc/news/coherus-announces-clinical-collaboration-storm-123000609</guid>
<pubDate>Tue, 27 May 2025 12:30:00 GMT</pubDate>
<description>– First patient dosed in a Phase 1b/2 study evaluating STC-15, a METTL3 inhibitor, in combination with LOQTORZI, a next-generation PD-1 inhibitor –REDWOOD CITY, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS), today announced a clinical collaboration with STORM Therapeutics, Ltd. (“STORM”) to evaluate STC-15, a METTL3 inhibitor, in combination with LOQTORZI (toripalimab-tpzi), a next-generation PD-1 inhibitor, in a Phase 1b/2 study for the treatment o</description>
</item>
<item>
<title>Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/coherus-biosciences-inc/news/coherus-biosciences-reports-first-quarter-201500480</link>
<guid isPermaLink="true">https://6ix.com/company/coherus-biosciences-inc/news/coherus-biosciences-reports-first-quarter-201500480</guid>
<pubDate>Mon, 12 May 2025 20:15:00 GMT</pubDate>
<description>– Strategic transformation to innovative oncology completed in Q2 2025 – – Positive CHS-114 (anti-CCR8 antibody) Phase 1b dose expansion study data in patients with head and neck cancer presented at 2025 AACR Annual Meeting – – Additional CHS-114 Phase 1b studies in 2L gastric cancer and 2L HNSCC ongoing – – Enrollment ongoing in the Phase 2 randomized trial of casdozokitug/toripalimab/bevacizumab in 1L HCC, with first data readout expected in 1H 2026 – – LOQTORZI net revenue was $7.3 million an</description>
</item>
</channel>
</rss>